Innovent Biologics

Innovent gets seven drugs on China's 2026 NRDL, four new

SUZHOU -- November 14, 2026 -- Innovent Biologics (HKEX: 01801) had seven products included or renewed in China's updated National Reimbursement Drug List (NRDL), four of them first-time listings. The list takes effect on January 1, 2027. CEO Michael Yu says the company's NRDL-covered lineup has expanded to 17 products that have cumulatively benefited more than 20 million patients. By our calculation, the seven decisions in this round touch about 41% of that lineup (7 of 17).

Four Innovent products enter the NRDL for the first time

The new entries are mazdutide, PECONDLE (picankibart), TABOSUN (ipilimumab N01) and VANFLYTA (quizartinib). The other three were already listed. TYVYT (sintilimab) and JAYPIRCA (pirtobrutinib) gained indications, and SINTBILO (tafolecimab) was renewed.

Innovent's Tafolecimab Cuts LDL-C 65% in Phase 3 Monotherapy Trial

Suzhou – November 08, 2026 -- Innovent Biologics (HKEX: 01801) said its PCSK9 antibody SINTBILO (tafolecimab) cut LDL-C by 65.19% at week 12 as monotherapy in the Phase 3 CREDIT-5 study, meeting the primary endpoint. The company plans to file a new-indication application with China's National Medical Products Administration (NMPA) "in the near future".

CREDIT-5 trial shows placebo-adjusted LDL-C drops above 58 points in both dosing regimens

The multi-center, randomized, double-blind, placebo-controlled study enrolled 198 Chinese participants with non-familial hypercholesterolemia and mixed hyperlipidemia. Of these, 131 received tafolecimab and 67 received placebo. Patients were randomized 2:1:2:1 to tafolecimab 150 mg every two weeks (Q2W), placebo Q2W, tafolecimab 450 mg every four weeks (Q4W) or placebo Q4W, after a 4-week run-in during which lipid-lowering products were prohibited.

Innovent's IBI3003 Hits 84.6% Response Rate in Myeloma Trial

San Francisco – September 29, 2026 -- Innovent Biologics reported an 84.6% overall response rate for its trispecific antibody IBI3003 at the recommended Phase 2 dose in heavily pretreated multiple myeloma patients, data presented in an oral session at the 23rd International Myeloma Society Annual Meeting 2026.

Trial identifies 360 μg/kg as the optimal dose after testing three dose levels

Among 26 patients treated at 360 μg/kg with a median follow-up of 7.57 months, median progression-free survival has not yet been reached. The cohort produced 11 stringent complete responses, 4 very good partial responses, and 7 partial responses. Response rates climbed to 94.7% among 19 patients who had received only 2 to 4 prior lines of therapy, and 92.3% among 13 patients without extramedullary disease.

Innovent to Unveil Phase 3 Gastric Cancer ADC Data at ESMO 2026

Suzhou, China – September 24, 2026 -- Innovent Biologics (HKEX: 01801) will present late-breaking Phase 3 data for its CLDN18.2-targeting antibody-drug conjugate IBI343/TAK-921 at the 2026 European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, running October 23-27.

Phase 3 gastric cancer trial secures late-breaking oral slot

Results from the registrational G-HOPE-001 study, comparing Arcotatug Tavetecan against treatment of physician's choice in previously treated advanced gastric or gastroesophageal junction adenocarcinoma, will be delivered as a late-breaking abstract (LBA77) during the October 23 proffered paper session. Dr. Kohei Shitara of Chiba, Japan, will present the first interim analysis of the randomized, open-label trial.